• Juan C Olivares-Gazca, Jose M Priesca-Marín, Martín Ojeda-Laguna, Javier Garces-Eisele, Silvia Soto-Olvera, Abraham Palacios-Alonso, Judith Izquierdo-Vega, Rómulo Chacon-Cano, Daniel Arizpe-Bravo, Miguel A López-Trujillo, Yahveth Cantero-Fortiz, Danitza Fernandez-Lara, Guillermo J Ruiz-Delgado, and Guillermo J Ruiz-Argüelles.
• Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, Pue, Mexico.
• Rev Invest Clin. 2020 Jan 1; 72 (3): 159-164.

BackgroundThe ideal treatment of coronavirus disease (COVID)-19 has yet to be defined, but convalescent plasma (CoPla) has been successfully employed.ObjectiveThe objective of the study was to study the safety and outcomes of the administration of CoPla to individuals with severe COVID-19 in an academic medical center.MethodsTen patients were prospectively treated with plasma from COVID-19 convalescent donors.ResultsOver 8 days, the sequential organ failure assessment score dropped significantly in all patients, from 3 to 1.5 (p = 0.014); the Kirby index (PaO2/FiO2) score increased from 124 to 255, (p < 0.0001), body temperature decreased significantly from 38.1 to 36.9°C (p = 0.0058), and ferritin levels also dropped significantly from 1736.6 to 1061.8 ng/ml (p = 0.0001). Chest X-rays improved in 7/10 cases and in 6/10, computerized tomography scans also revealed improvement of the lung injury. Decreases in C-reactive protein and D-dimer levels were also observed. Three of five patients on mechanical ventilation support could be extubated, nine were transferred to conventional hospital floors, and six were sent home; two patients died. The administration of CoPla had no side effects and the 24-day overall survival was 77%.ConclusionsAlthough other treatments were also administered to the patients and as a result data are difficult to interpret, it seems that the addition of CoPla improved pulmonary function.Copyright: © 2020 Permanyer.

51 keywords...

hide…